Proton Pump Inhibitors Market Report 2025

The proton pump inhibitors market size has grown steadily in recent years. It will grow from $3.4 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to the prevalence of gastroesophageal reflux disease (GERD), peptic ulcer disease incidence, rising aging population, changing lifestyles, and dietary habits, and increasing awareness and diagnosis.

The proton pump inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to emerging markets adoption, growth in helicobacter pylori infections, patient education initiatives, strategic marketing, and promotions. Major trends in the forecast period include integration with digital health solutions, global market expansion, focus on gastrointestinal health education, regulatory updates, and safety measures, and environmental impact considerations.

The growth of the proton pump inhibitors market is anticipated to be driven by the increasing prevalence of gastrointestinal disorders. Gastrointestinal disorders encompass a range of conditions affecting the gastrointestinal (GI) tract, including nausea, vomiting, food poisoning, and diarrhea. Proton pump inhibitors (PPIs) play a crucial role in managing heartburn and acid-related disorders by reducing the production of stomach acid. The rising incidence of gastrointestinal disorders, as evidenced by statistics from organizations such as Cancer Australia, where stomach cancer cases are projected to reach 2,572 in 2022, underscores the demand for PPIs in addressing these health challenges. Additionally, insights from the American Gastroenterological Association reveal that severe gastrointestinal symptoms have led over 40% of Americans to curtail daily activities in the past year. This substantial impact on individuals' lives further emphasizes the need for effective treatments such as proton pump inhibitors.

The increased occurrence of Helicobacter pylori infections is expected to contribute to the growth of the proton pump inhibitor market. Helicobacter pylori is a bacterial infection affecting the upper part of the small intestine and the stomach lining. PPIs are commonly prescribed as part of treatment plans for H. pylori infections, often in combination with antibiotics. The global prevalence of H. pylori infections, highlighted by the Best Practice Advocacy Centre New Zealand, with over 50% of people worldwide infected and higher rates in Africa, Asia, and Latin America, emphasizes the widespread need for effective therapies such as proton pump inhibitors to address this bacterial infection. This dual influence of gastrointestinal disorders and H. pylori infections underscores the significant role PPIs play in addressing prevalent health issues and driving market growth.

Major companies in the proton pump inhibitors market are focusing on technological advancements, such as the introduction of Rabeprazole + Levosulpiride SR Capsules, to enhance the treatment of acid-related disorders. These capsules are a novel medication aimed at addressing gastrointestinal issues like gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS). For example, in June 2024, Akums Drugs & Pharmaceuticals, an India-based pharmaceutical company, launched the Rabeprazole + Levosulpiride SR Capsules. This combination medication is designed to treat acid-related gastrointestinal disorders, including GERD, functional dyspepsia, and other conditions associated with excess stomach acid and impaired digestive motility.

Companies in the proton pump inhibitor market are also directing their efforts towards obtaining approvals for innovative products. One such instance is the U.S. Food and Drug Administration (FDA) approval of KONVOMEP, an oral suspension containing omeprazole and sodium bicarbonate. This product aims to treat active benign gastric ulcers and reduce the risk of upper gastrointestinal bleeding in critically ill patients. KONVOMEP, being a liquid mixture of sodium bicarbonate and the proton pump inhibitor omeprazole, is particularly beneficial for individuals who have difficulty swallowing tablets or capsules. Azurity Pharmaceuticals, Inc., a US-based pharmaceutical company, secured FDA approval for Konvomep in September 2022, addressing the need for liquid medication options, especially for those with difficulty swallowing solid oral doses.

In July 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, acquired the Abbreviated New Drug Application (ANDA) for famotidine tablets from Wockhardt, marking a strategic move in expanding its presence in the American over-the-counter (OTC) market. The acquired ANDA includes famotidine tablets, cetirizine hydrochloride tablets, lansoprazole delayed-release capsules, and olopatadine hydrochloride ophthalmic solution. This acquisition reflects Glenmark's commitment to ensuring patient access to high-quality and affordable medications.

Major companies operating in the proton pump inhibitors market include AstraZeneca plc, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company, Santarus Inc., Janssen Pharmaceuticals, GlaxoSmithKline plc, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Sanofi S.A., Johnson & Johnson, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Cipla Limited, Hetero Drugs Limited, Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Limited, Panacea Biotec Ltd., Strides Pharma Science Limited, Wockhardt Ltd.

North America was the largest region in the proton pump inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global proton pump inhibitors market size during the forecast period. The regions covered in the proton pump inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proton pump inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Proton pump inhibitors (PPIs) constitute a category of medications designed to diminish the production of stomach acid. They find application in addressing conditions arising from either an excessive production of stomach acid or conditions aggravated by such acidity, including acid reflux and stomach ulcers.

The primary types of proton pump inhibitors encompass pantoprazole, omeprazole, lansoprazole, esomeprazole, rabeprazole, dexlansoprazole, and other derivatives. Pantoprazole, belonging to the proton pump inhibitor class, operates by reducing the volume of acid generated by the stomach. These medications play a crucial role in the treatment of ulcers, gastroesophageal reflux disease (GERD), and other related conditions. The usage of proton pump inhibitors is widespread in various healthcare settings, including hospitals, clinics, and other treatment centers, where they contribute significantly to managing acid-related disorders.

The proton pump inhibitors market research report is one of a series of new reports that provides proton pump inhibitors market statistics, including proton pump inhibitors industry global market size, regional shares, competitors with a proton pump inhibitors market share, detailed proton pump inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the proton pump inhibitors industry. This proton pump inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proton pump inhibitors market consists of sales of pantoprazole, and lansoprazole DR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.